Ischemia-reperfusion injury: Complex pathophysiology with elusive treatment

Hellenic J Cardiol. 2018 Nov-Dec;59(6):329-330. doi: 10.1016/j.hjc.2018.11.002. Epub 2018 Nov 16.

Authors

Nikolaos Papageorgiou¹, Alexandros Briasoulis², Dimitris Tousoulis³

Affiliations

¹ Electrophysiology Department, Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom. Electronic address: drnpapageorgiou@yahoo.com.
² Division of Cardiovascular Diseases, University of Iowa, Iowa City, IA, United States.
³ 1(st) Cardiology Department, Athens University Medical Schoοl, Hipporkation Hospital, Athens, Greece.

PMID: 30448621
DOI: 10.1016/j.hjc.2018.11.002

No abstract available

Keywords: Ischemia-reperfusion; Myocardial infarction; Therapy.

Publication types

Editorial

MeSH terms

Adrenergic beta-1 Receptor Antagonists / therapeutic use
Animals
Cardiovascular Agents / therapeutic use
Cyclopropanes / administration & dosage
Cyclopropanes / therapeutic use
Disease Models, Animal
Humans
Ischemic Preconditioning, Myocardial / methods
Ischemic Preconditioning, Myocardial / veterinary
Metoprolol / administration & dosage
Metoprolol / therapeutic use
Myocardial Ischemia / drug therapy*
Myocardial Ischemia / pathology
Myocardial Reperfusion Injury / metabolism
Myocardial Reperfusion Injury / pathology
Myocardial Reperfusion Injury / physiopathology*
Myocardial Reperfusion Injury / prevention & control*
Myocardium / metabolism
Myocardium / pathology*
Myocytes, Cardiac / metabolism
Protein Kinase Inhibitors / therapeutic use
Pyridines / administration & dosage
Pyridines / therapeutic use
Ventricular Dysfunction, Left / drug therapy
Ventricular Dysfunction, Left / physiopathology

Substances

6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-N-(2,2-dimethylprpyl)-3-pyridinecarboxamide
Adrenergic beta-1 Receptor Antagonists
Cardiovascular Agents
Cyclopropanes
Protein Kinase Inhibitors
Pyridines
Metoprolol